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ABSTRACT
The virus SARS-COV-2 caused disease COVID-19 has been declared a pandemic by WHO. Currently, over
210 countries and territories have been affected. Careful, well-designed drugs and vaccine for the total
elimination of this virus seem to be the need of the hour. In this context, the invivo mathematical modelling
studies can be extremely helpful in understanding the efficacy of the drug interventions. These studies can
also help understand the role of the crucial inflammatory mediators and the behaviour of immune response
towards this novel coronavirus. Motivated by these facts, in this paper, we study the invivo dynamics of
Covid-19. We initially model and study the natural history, the course of the infection and its dynamics. We
then validate the model by generating two-parameter heat plots that represent the characteristics of Covid-
19. We also do the sensitivity analysis to identify the sensitive parameters of the system. Lastly, we study
the efficacy of drug interventions for Covid-19 by formulating an Optimal Control Problem. The outcomes
of these studies are multi-fold. The system admits two steady states: the disease-free equilibrium and the
infected equilibrium. The dynamics of the system show that the disease takes its course to one of these steady
states based on the reproduction number R0. The system undergoes a transcritical bifurcation at R0 = 1.
From the sensitivity analysis, it is seen that the burst rate of the virus particles and the natural death rate
of the virus are the sensitive parameters of the system. Results from the optimal control studies suggest that
the antiviral drugs that target viral replication and the drugs that enhance the immune system response both
reduce the infected cells and viral load when taken individually. However, it is observed that these drugs
yield the best possible results when administered together. Hence, it is concluded that the optimal control
strategy would be to use the combination of both these drugs which not only help in patient’s recovery but
also reduce the side effects caused to the patient because of the minimal/optimal dosage administered. The
results obtained here are inline with some of the clinical findings for Covid-19. This invivo modelling study
involving the crucial biomarkers of Covid-19 is the first of its kind and the results obtained from this can be
helpful to researchers, epidemiologists, clinicians and doctors who are working in this field.
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1 INTRODUCTION
The Coronavirus caused disease COVID-19 has been declared a pandemic by WHO. Currently, over 210
countries and territories have been affected. As on 02nd May 2020, 2, 37, 996 people have lost their lives
and more than 33 lakh people have been affected due to Covid-19 all over the world [4]. This pandemic
has catalysed the development of novel coronavirus vaccines across pharmaceutical companies and research
organizations. Drugs such as remdesivir, favipiravir, ivermectin, lopinavir/ritonavir, mRNA-1273, phase I
trial (NCT04280224) and AVT technology are being used as therapeutic agents by different countries for
treating Covid-19 [1, 2, 3, 29].
In this context, the invivo mathematical modelling studies can be extremely helpful in understanding
the efficacy of the drug/medicine administered. These studies can also help in understanding the behaviour
of cytokines, chemokines and immune system response of the body towards this virus [24, 26]. The results
of these studies can suggest the optimal drug regime for treating Covid-19.
Motivated by the above observations, in this paper, we propose to model and study the invivo dynamics
of Covid-19 with and without drug interventions to understand the efficacy of drugs administered. We study
these problems as Optimal Control Problems. In the recent work [12], an in-host modelling study deals with
the qualitative characteristics and estimation of standard parameters of corona viral infections. Some of the
mathematical models that deal with transmission and spread of COVID-19 at the population level can be
found in [9, 17, 20, 30]. Modelling the Invivo dynamics of Covid-19 involving the crucial biomarkers, which
is being attempted here is the first of its kind for Covid-19.
The section-wise split-up of the paper is as follows: In the next section, we discuss the pathogenesis
of Covid- 19 and formulate the mathematical model dealing with natural history. Further, we discuss
the antiviral drug interventions that are being tried across the nations and then we develop the invivo
model incorporating these interventions. In the later sections, we discuss the disease dynamics, we frame
the optimal control problem and do the optimal control studies. Finally, we present the discussions and
conclusions followed by a few pointers to future research in this direction.
2 MATHEMATICAL MODELS FORMULATION
PATHOGENSIS OF COVID-19
On Feb. 11, 2020 World Health Organization named novel corona viral pneumonia induced as Coron-
avirus disease(COVID-19), which is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2).
Out of four coronavirus genera(α, β, γ, δ), β CoV strain showed 88% identity of genetic sequence with
two bat derived SARS corona viruses (bat-SL-CoVZXC45,bat-SL-CoVZXC21) and 50% with virus causing
Middle East Respiratory Syndrome(MERSCoV) [22]. Therefore the functional mechanism in pathogenesis
is also quite resembling with SARS CoV and MERSCoV.
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Human to human transmission of SARS-CoV-2 occurs either through droplet infection or direct contact
from an infected person. Transmission from asymptomatics and through faeco-oral route are also reported.
After the entry of virus through droplet infection or through contact transmission from hands to the mucous
membrane of mouth, nose or eyes. It is reported that Angiotensin Converting Enzyme-2 (ACE-2) plays
crucial role in providing binding site to the viral structural protein(Spike protein-S) on the cell surface and
subsequent entry into the host cell [27]. The SARS-CoV-2 have much higher affinity towards ACE-2 recep-
tors as compared with its previous conterparts(SARS-CoV and MERS-CoV). The ACE-2 expresses in lung
alveolar Type-2 cells(AT2), liver cholangiocytes, colon colonocytes, esophagus, keratinocytes, endothelial
cells of ileum, rectum and stomach, and proximal tubules of kidneys. AT2 secret surfactant, which reduces
surface tension preventing collapsing of the alveoli and playing crucial role in oxygen diffusion across lungs
and blood vessels.Viral antigens are presented by antigen presenting cells(APC) which are Human Leucocyte
Antigen(HLA) cytotoxic T cell(also known as T-killer cell, cytotoxic T-lymphocyte, CD8+) [18]. The virus
enters the cell with fusion of its membranes with host cell and begins transcription with ssRNA acting as tem-
plate. Synthesis of the viral proteins takes place in the cytoplasm of the pneumocytes, new virus is released
by budding and ready to infect new cell which is confirmed by presence of abundent viral antigens in the
cytoplasm of the pneumocytes(AT2) in case of SARS-CoV [31]. Viremia (viral particle in the blood/serum)
was also noticed by some authors along with very high levels of IL-6 especially among severe cases of Covid-19
illness leading to increase vascular permeability and impairment of organs [10]. Acute Respiratory Distress
Syndrome(ARDS) is the common immunopathological event for all the aforesaid corona viral diseases.One
of the main mechanisms in causation of ARDS is cytokine storm,deadly uncontrolled systemic inflammatory
response due to the release of large quantity of pro-inflammatory cytokines and chemokines by immune ef-
fector cells. These cytokines are identified as IFN-α, IFN-γ, IL-1b, IL-6, IL-2, IL-18, IL-33, TNF-α, TGF-β
and chemokines as CCL-2, CCL-3, CCL-5, CXCL-8, CXCL-9, CXCL-10. Severe infections correlated high
levels of IL-6, IFN α, CCL-5, CXCL-8 and CXCL-10 [10, 18]. Also the viral load was noted to be crucial
in determining severity of the disease and strongly correlated with the lung injury Murray score [21]. The
cytokine storm is a violent attack by the immune system causing ARDS, multi-organ failure and eventually
death [18].
From the above discussed pathogenesis it can be understood that the study of both the epithelial
(pneumocytes) cells (including both the healthy and infected) and virus population levels and their changes
over the time due to inflammatory mediators play a crucial in understanding the dynamics of pneumonia
inflated COVID-19.
Motivated by these we first consider the following mathematical model.
Model 1 : Model without Interventions/Medication
dS
dt
= ω − βSV − µS
dI
dt
= βSV −
(
d1 + d2 + d3 + d4 + d5 + d6
)
I − µI
dV
dt
= αI −
(
b1 + b2 + b3 + b4 + b5 + b6
)
V − µ1V
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Parameters Biological Meaning
S Healthy Type II Pneumocytes
I Infected Type II Pneumocytes
ω Natural birth rate of Type II Pneumocytes
V Viral load
β Rate at which healthy Pneumocytes are infected
α Burst rate of virus particles
µ Natural death rate of Type II Pneumocytes
µ1 Natural death rate of virus
d1, d2, d3, d4, d5, d6 Rates at which Infected Pneumocytes are removed because
the release of cytokines and chemokines IL-6
TNF-α, INF-α, CCL5, CXCL8 , CXCL10 respectively
b1, b2, b3, b4, b5, b6 Rates at which Virus is removed because of
the release of cytokines and chemokines IL-6
TNF-α, INF-α, CCL5, CXCL8 , CXCL10 respectively
u2(t) Rate at which virus replication/birth is decreased due to medication
The purpose of drug interventions can be two fold, the first to target the virus replication cycle and
the second based on immunotherapy approaches either aimed to boost innate antiviral immune responses or
alleviate damage induced by dysregulated inflammatory responses. Based on this the therapeutic agents for
virus infections can be divided into two categories each serving the designated purpose [29].
Drugs such as remdesivir, favipiravir inhibit RNA-dependent RNA polymerase and drugs ivermectin,
lopinavir/ritonavir inhibit the viral protease there by reducing the viral replication. On the other hand
clinical trials such as phase I trial (NCT04280224) in China aim to enhance the innate immune system by
increasing the production of cytokines and chemokines with the end goal of increasing NK cells [29].
Motivated by the above clinical findings we consider an control problem with the following drug inter-
ventions as controls.
u11(t) = d1(t) + d1(t) + d2(t) + d3(t) + d4(t) + d5(t) + d6(t)
u12(t) = b1(t) + b1(t) + b2(t) + b3(t) + b4(t) + b5(t) + b6(t)
and u2(t)
Here the controls u11 and u12 incorporate the effect of drug interventions which enhance the innate
immune response which in turn leads to decrease in the infected population and viral load. The control u2
incorporates the effect of drug interventions which prevent viral replication thereby reducing the virus birth
rate.
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Model 2 : Model with Interventions/Medication as Controls
dS
dt
= ω − βSV − µS
dI
dt
= βSV −
((
d1(t) + d2(t) + d3(t) + d4(t) + d5(t) + d6(t)
)
= u11(t)
)
I − µI
dV
dt
= (α− u2(t))I −
((
b1(t) + b2(t) + b3(t) + b4(t) + b5(t) + b6(t)
)
= u12(t)
)
V − µ1V
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In this section we consider model 1 which deals with the natural history and course of infection. We study
its dynamics.
POSITIVITY AND BOUNDEDNESS
The positivity and boundedness of the solutions of the model is the fundamental thing which needs to be
established before doing any other analysis.
Positivity: We now show that if the initial conditions of the model 1 are positive, then the solution remain
positive for any future time. Using the model 1 equations, we get,
dS
dt
∣∣∣∣
S=0
= ω ≥ 0, dI
dt
∣∣∣∣
I=0
= βSV ≥ 0,
dB
dt
∣∣∣∣
B=0
= αI ≥ 0.
Thus all the above rates are non-negative on the bounding planes (given by S = 0, I = 0, and V = 0)
of the non-negative region of the real space. So, if a solution begins in the interior of this region, it will
remain inside it throughout time t. This happens because the direction of the vector field is always in the
inward direction on the bounding planes as indicated by the above inequalities. Hence, we conclude that
all the solutions of the Model remain positive for any time t > 0 provided that the initial conditions are
positive. This establishes the positivity of the solutions of the model 1. Next we will show that the solution
is bounded.
Boundedness: Let N(t) = S(t) + I(t) + V (t)
Let x = d1 + d2 + d3 + d4 + d5 + d6 and y = b1 + b2 + b3 + b4 + b5 + b6
5
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Now,
dN
dt
=
dS
dt
+
dI
dt
+
dV
dt
= ω − µ(S + I)− µ1V − (x− α)I − yV
≤ ω − µ(S + I + V )
with the assumption that x > α and µ = µ1.
Here the integrating factor is eµt. Therefore after integration we get,
N(t) ≤ ωµ + ce−µt. Now as t→∞ we get,
N(t) ≤ ω
µ
Thus we have shown that model 1 is positive and bounded. Therefore the biologically feasible region is given
by the following set,
Ω =
{(
S(t), I(t), B(t)
)
∈ R3+ : S(t) + I(t) + V (t) ≤
ω
µ
, t ≥ 0
}
EQUILIBRIUM POINTS AND REPRODUCTION NUMBER (R0)
Model 1 has two equilibrium points namely, the infection free equilibrium E0 =
(
ω
µ , 0, 0
)
and the infected
equilibrium E1 = (S∗, I∗, V ∗), where,
S∗ =
(y + µ1)(x+ µ)
αβ
I∗ =
αβω − µ(y + µ1)(x+ µ)
αβ(x+ µ)
V ∗ =
αβω − µ(y + µ1)(x+ µ)
β(x+ µ)(y + µ1)
and
x = d1 + d2 + d3 + d4 + d5 + d6
y = b1 + b2 + b3 + b4 + b5 + b6
6
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The basic reproduction number is calculated using the next generation matrix method [11] and the expres-
sion for R0 is given by
R0 =
βαω
µ(x+ µ)(y + µ1)
LOCAL DYNAMICS AND GLOBAL DYNAMICS OF THE MODEL 1
In the following we discuss the local stability analysis of the infection free equilibrium E0 and infected
equilibrium E1.
STABILITY ANALYSIS OF E0
The jacobian matrix of the model 1 at the infection free equilibrium E0 is given by,
JE0 =
−µ 0
−βω
µ
0 −(x+ µ) βωµ
0 α −(y + µ1)

The characteristics equation is given by,
(
− µ1 − λ
)(
λ2 +
(
x+ y + µ+ µ1
)
λ+ (x+ µ)(y + µ1)− βαω
µ
)
= 0 (4)
The first root of equation (4) is λ1 = −µ1
Now from the definition of R0 we get,
βαω − µ(x+ µ)(y + µ1)y = µ(R0 − 1)(x+ µ)(y + µ1)
7
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The roots of the quadratic part of equation (4), are given by,
λ2,3 = A±
√
A2 + 4(R0 − 1)D
where,
A = (x+ y + µ+ µ1)
and
D = (x+ µ)(µ1 + y)
There are two cases that we need to consider here.
case I: When R0 < 1
When R0 < 1 there are further two subcases,
(a): A2 + 4(R0 − 1)D > 0
(b): A2 + 4(R0 − 1)D < 0
Sub-case (a): When A2 + 4(R0 − 1)D > 0, both the eigenvalues λ2,3 are negative,
λ2,3 = A±
√
A2 + 4(R0 − 1)D < 0
Hence all the eigen values of the characteristics equation (4) are negative. Therefore the infection free equi-
librium point E0 is asymptotically stable.
Sub-case (b): When A2 +4(R0−1)D < 0 the eigenvalues of the quadratic part of equation (4) are complex
conjugates with the negative real parts. Therefore we again have E0 to be locally asymptotically stable.
Hence we conclude that E0 is locally asymptotically stable provided R0 < 1
case II: When R0 > 1
For the case R0 > 1, the characteristics equation (4) has two negative eigenvalues and one positive eigen-
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value. Therefore whenever R0 > 1 the infection free equilibrium E0 is unstable.
STABILITY ANALYSIS OF E1
With the definition of R0 the infected equilibrium is given by,
E1 = (S
∗, I∗, B∗)
where,
S∗ =
(x+ µ)(y + µ1)
αβ
I∗ =
µ(µ1 + y)
(
R0 − 1
)
αβ
V ∗ =
µ
(
R0 − 1
)
β
Therefore the infected equilibrium exists only if R0 > 1, otherwise E1 will become negative which does not
make sense.
The jacobian matrix of the model 1 is given by,
J =
−βV − µ 0 −βSβV −(x+ µ) βS
0 α −(y + µ1)

The characteristic equation of the jacobian J evaluated at E1 is given by,
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λ3 +
(
p+ µR0
)
λ2 +
(
pµR0
)
λ+ qµ
(
R0 − 1
)
= 0 (5)
where p = x+ y + µ+ µ1 and q = (x+ µ)(µ1 + y).
Since R0 > 1, (p+ µR0) > 0, (pµR0) > 1 and qµ(R0 − 1) > 0 (because R0 > 1 for E1 to exists). Therefore
if we substitute λ = −k in equation (5) using Descartes rule of sign change we get all the roots of (5) to
be negative. Hence we conclude that the infected equilibrium point E1 exists and remains asymptotically
stable provided R0 > 1.
GLOBAL DYNAMICS OF THE MODEL 1
GLOBAL STABILITY OF E0
To establish the global stability of the infection free equilibrium E0 we make use of the method discussed in
Castillo-Chavez et al [7].
Theorem 1
Consider the following general system,
dX
dt
= F (X,Y )
dY
dt
= G(X,Y )
where X denotes the uninfected population compartments and Y denotes the infected population com-
partments including latent, infectious etc. Here the function G is such that it satisfies G(X, 0) = 0. Let
U0 = (X0, 0¯) denote the equilibrium point of the above general system.
If the following two conditions are satisfied then the infection free equilibrium point U0 is globally asymp-
totically stable for the above general system provided R0 < 1
A1: For the subsystem dXdt = F (X, 0), X0 is globally asymptotically stable.
A2: The function G = G(X,Y ) can be written as G(X,Y ) = AY − Ĝ(X,Y ), where Ĝj(X,Y ) ≥ 0 ∀ (X,Y )
in the biologically feasible region Ω for j=1,2 and A = DYG(X,Y ) at (X0, 0¯) is a M-matrix(matrix with
non-negative off diagonal element).
10
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Now we will prove the global stability of E0 = (ωµ , 0, 0) of model 1 by showing that model 1 can be written
as the above general form and both the conditions A1 and A2 are satisfied .
Comparing the above general model to our model 1 the functions F and G are given by
F (X,Y ) = ω − βSV − µS
G(X,Y ) =
(
βV S − (x+ µ)I, αI − (y + µ1)V
)
where X = S and Y = (I, V )
The disease free equilibrium point is U0 = (X0, 0¯), where,
X0 =
ω
µ
and 0¯ = (0, 0)
From the stability analysis of E0, we know that U0 is locally asymptotically stable iff R0 < 1. Clearly, we
see that G(X, 0¯) = (0, 0¯). Now, we show that X0 = (ωµ ) is globally asymptotically stable for the subsystem
dS
dt
= F (S, 0¯) = ω − µS (6)
The integrating factor is eµt and therefore after performing integration on the above equation (6) we get,
S(t)eµt =
ωeµt
µ
+ c
As t→∞ we get,
S(t) =
ω
µ
which is independent of c. This independency implies that X0 = ωµ1 is globally asymptotically stable for the
subsystem dSdt = ω − µS. So, the assumption A1 is satisfied.
Now, we will show that assumption A2 holds. First, we will find the matrix A. As per the theorem,
A = DYG(X,Y ) at X = X0 and Y = 0¯. Now
DYG(X,Y ) =
−(x+ µ) βS
α −(y + µ1)

11
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At X = X0 and Y = 0¯, we obtain,
A =
−(x+ µ) βωµ
α −(y + µ1)

Clearly, matrix A has non-negative off-diagonal elements. Hence, A is a M-matrix. Using Ĝ(X,Y ) =
AY −G(X,Y ), we get,
Ĝ(X,Y ) =
Ĝ1(X,Y )
Ĝ2(X,Y )
 =
βV (ωµ − S)
0

Hence Ĝ1(X,Y ) = βV (ωµ − S) ≥ 0 because S(t) ≤ ωµ since S(t) + I(t) + V (t) ≤ ωµ and Ĝ2(X,Y ) = 0
Thus both the assumptions A1 and A2 are satisfied and therefore infection free equilibrium point E0 is
globally asymptotically stable provided R0 < 1.
GLOBAL STABILITY OF E1
From the definition of infected equilibrium E1 we get the following relations
1. µS∗ = ω − (x+ µ)I∗
2. βS∗V ∗ = (x+ µ)I∗
3. αI∗ = (y + µ1)V ∗
We define the Lyaponov function as,
L(S, I, V ) =
(
(S−S∗)+(I−I∗)
)2
2 +
(I−I∗)2
2 +
(V−V ∗)2
2 .
Differentiating L with respect to time we get,
dL
dt
=
(
(S − S∗) + (I − I∗)
)
d(S + I)
dt
+ (I − I∗)dI
dt
+ (V − V ∗)dV
dt
=
(
(S−S∗)+(I−I∗)
)(
ω−µS−(x+µ)I
)
+(I−I∗)
(
βSV−(x+µ)I
)
+(V−V ∗)
(
αI−(y+µ1)
)
12
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Using the above relations 1, 2 and 3 we get the following,
dL
dt
=
(
(S−S∗)+(I−I∗)
)(
µS∗+I∗(x+µ)−µS−(x+µ)I
)
+(I−I∗)
(
βS(V−V ∗)+βV ∗(S−S∗)−(x+µ)(I−I∗)
)
+(V − V ∗)
(
α(I − I∗)− (y + µ1)(V − V ∗)
)
=
(
(S−S∗)+(I− I∗)
)(
−µ(S−S∗)− (x+µ)(I− I∗)
)
+βS(V −V ∗)(I− I∗)+βV ∗(S−S∗)(I− I∗)
−(x+ µ)(I − I∗)2 + α(V − V ∗)(I − I∗)− (y + µ1)(V − V ∗)2
Further simplifying we get,
dL
dt
= −
(
x+2µ+βV ∗
)
(S−S∗)(I−I∗)+(βS+α)(V−V ∗)(I−I∗)−µ(S−S∗)2−(x+µ)(I−I∗)2−(y+µ1(V−V ∗)2
Now we assume
(
x+ 2µ+βV ∗
)
(S−S∗)(I − I∗) > 0 and
(
x+ 2µ+βV ∗
)
(S−S∗)(I − I∗) > (βS+α)(V −
V ∗)(I − I∗) whenever (βS + α)(V − V ∗)(I − I∗) > 0
Thus dLdt ≤ 0 and dLdt = 0 iff S = S∗, I = I∗, and V = V ∗
Hence by Lyapunov Lasalle theorem [25], the infected equilibrium E1 is globally asymptotically stable.
BIFURCATION ANALYSIS
In this section we use the method given by Chavez and Song in [8] to do the bifurcation analysis.
Theorem 2
Consider a system,
dX
dt
= f(X,φ)
where X ∈ Rn, φ ∈ R is the bifurcation parameter and f : Rn ×R→ Rn where f ∈ C2(Rn,R). Let 0¯ be the
equilibrium point of the system such that f(0¯, φ) = 0¯,∀ φ ∈ R. Let the following conditions hold :
1. For the matrix A = DXf(0¯, 0), zero is the simple eigenvalue and all other eigenvalues have negative
real parts.
2. Corresponding to zero eigenvalue, matrix A has non-negative right eigenvector, denoted as u and
non-negative left eigenvectors, denoted as v.
13
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Let fk be the kth component of f . Let a and b be defined as follows -
a =
n∑
k,i,j=1
[
vkwiwj
(
∂2fk
∂xi∂xj
(0¯, 0)
)]
b =
n∑
k,i=1
[
vkwi
(
∂2fk
∂xi∂φ
(0¯, 0)
)]
Then local dynamics of the system near the equilibrium point 0¯ is totally determined by the signs of a and
b. Here are the following conclusions :
1. If a > 0 and b > 0, then whenever φ < 0 with | φ | 1, the equilibrium 0¯ is locally asymptotically
stable, and moreover there exists a positive unstable equilibrium. However when 0 < φ  1, 0¯ is an
unstable equilibrium and there exists a negative and locally asymptotically stable equilibrium.
2. If a < 0, b < 0, then whenever φ < 0 with | φ 1, 0¯ is an unstable equilibrium whereas if 0 < φ 1,
0¯ is locally asymptotically stable equilibrium and there exists a positive unstable equilibrium.
3. If a > 0, b < 0, then whenever φ < 0 with | φ | 1, 0¯ is an unstable equilibrium, and there exists
a locally asymptotically stable negative equilibrium. However if 0 < φ  1, 0¯ is stable, and a there
appears a positive unstable equilibrium.
4. If a < 0, b > 0, then whenever φ changes its value from negative to positive, the equilibrium 0¯ changes
its stability from stable to unstable. Correspondingly a negative equilibrium, unstable in nature,
becomes positive and locally asymptotically stable.
Applying the Theorem 2 to our Model 1 :
In our case, we have x = (S, I,B) ∈ R3 where x1 = S, x2 = I and x3 = V . Let us consider β (transmission
rate of the infection) to be the bifurcation parameter.
We know that R0 = βαωµ(p+µ)(q+µ1) where p = d1 + d2 + d3 + d4 + d5 + d6 and q = b1 + b2 + b3 + b4 + b5 + b6.
Therefore we have,
β =
R0µ(p+ µ)(q + µ1)
αω
Let β = β∗ at R0 = 1. So, we have,
β∗ =
µ(p+ µ)(q + µ1)
αω
With x = (x1, x2, x3) = (S, I, V ) model 1 can be written as follows :
14
3 NATURAL HISTORY, THE COURSE OF THE INFECTION AND ITS DYNAMICS
dx1
dt
= ω − βx1x3 − µx1 = f1
dx2
dt
= βx1x3 − (P + µ)x2 = f2
dx3
dt
= αx2 − (q + µ1)x3 = f3
The disease free equilibrium point E0 is given by,
x∗ =
(
ω
µ
, 0, 0
)
= (x∗1, x
∗
2, x
∗
3)
Clearly, f(x∗, β) = 0, ∀ β ∈ R, where f = (f1, f2, f3). Let Dxf(x∗, β∗) denote the Jacobian matrix of the
above system at the equilibrium point x∗ and R0 = 1. Now we see that,
Dxf(x
∗, β∗) =

−µ 0 −β∗ωµ
0 −(p+ µ) β∗ωµ
0 α −(q + µ1)

The characteristic polynomial of the above matrix is obtained as
(−µ− λ)
[
(−(p+ µ)− λ)(−(q + µ1)− λ)−
(
αβ∗ω
µ
)]
= 0
Hence, we obtain the first eigenvalue to be
λ1 = −µ < 0
The other eigenvalues λ2,3 are the solution the following equation,
λ2 +
(
p+ q + µ+ µ1
)
λ+ (p+ µ)(µ1 + q)− β
∗αω
µ
= 0
substituting for β∗ we get,
λ2 +
(
p+ µ+ q + µ1
)
λ = 0
Therefore the other eigen values are λ2 = 0 and λ3 = −(p+ q + µ+ µ1)
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Hence, the matrix Dxf(x∗, β∗) has zero as its simple eigenvalue and all other eigenvalues with negative real
parts. Thus, the condition 1 of the Theorem 2 is satisfied.
Next, for proving condition 2, we need to find the right and left eigenvectors of the zero eigenvalue (λ2). Let
us denote the right and left eigenvectors by u and v respectively. To find u, we use (Dxf(x∗, β∗)−λ2Id)u = 0,
which implies that

−µ 0 −β∗ωµ
0 −(p+ µ) β∗ωµ
0 α −(q + µ1)


u1
u2
u3
 =

0
0
0

where u = (u1, u2, u3)T . As a result, we obtain the system of simultaneous equations as follows :
−µu1 − β
∗ω
µ
u3 = 0
−(p+ µ)u2 + β
∗ω
µ
u3 = 0
αu2 − (q + µ1)u3 = 0
By choosing u3 = µ in the above simultaneous equation we obtain
u2 =
β∗ω
(p+ µ)
and u1 = −β
∗ω
µ
Therefore, the right eigen vector of zero eigenvalue is given by
u =
(
− β
∗ω
µ
,
β∗ω
(p+ µ)
, µ
)
Similarly, to find the left eigenvector v, we use v(Dxf(x∗, β∗)− λ2Id) = 0, which implies that
[
v1 v2 v3
]

−µ 0 −β∗ωµ
0 −(p+ µ) β∗ωµ
0 α −(q + µ1)
 =
[
0 0 0
]
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where v = (v1, v2, v3). The simultaneous equations obtained thereby are as follows :
−µ1v1 = 0
−µ1v2 + αv3 = 0
−β∗ω
µ1
v1 +
β∗ω
µ1
v2 − qv3 = 0
Therefore solving the above simultaneous equation we obtain v1 = 0.
By choosing v2 = 1 we get
v3 =
β∗ω
(p+ µ1)
Hence, the left eigen vector is given by
v =
(
0, 1,
β∗ω
(q + µ1)
)
Now, we need to find a and b. As per the Theorem 2, a and b are given by
a =
3∑
k,i,j=1
[
vkuiuj
(
∂2fk
∂xi∂xj
(x∗, β∗)
)]
b =
3∑
k,i=1
[
vkui
(
∂2fk
∂xi∂β
(x∗, β∗)
)]
Expanding the summation in the expression for a, it reduces to
a = u1u3
∂2f2
∂x1∂x3
+ u3
(
u1
∂2f2
∂x3∂x1
+ u3
∂2f2
∂x3∂x3
)
+ v3u3u3
∂2f3
∂x3∂x3
where partial derivatives are found at (x∗, β∗). Since we know u and v we only need to find the partial
derivatives in above expression. They are found to be
∂2f2
∂x1∂x3
(x∗, β∗) = β∗
∂2f2
∂x3∂x1
(x∗, β∗) = β∗
∂2f2
∂x3∂x3
(x∗, β∗) = 0
∂2f3
∂x3∂x3
(x∗, β∗) = 0
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Substituting these partial derivatives along with w and v in a, we get,
a = −2β∗2ω < 0
Next, expanding the summation in the expression for b, we get,
b = v2u3
(
∂2f2
∂x3∂β
(x∗, β∗)
)
The partial derivative in the above expression is found to be
∂2f2
∂x3∂β
(x∗, β∗) =
ω
µ
which implies,
b = ω > 0
We notice that condition (iv) of the theorem is satisfied. Hence, we conclude that the system undergoes
bifurcation at β = β∗ implying R0 = 1.
Thus, we conclude that when R0 < 1, there exists a unique disease free equilibrium which is globally asymp-
totically stable and negative infected equilibrium which is unstable . Since negative values of population
is not practical, therefore we ignore it in this case. Further, as R0 crosses unity from below, the disease
free equilibrium point loses its stable nature and become unstable, the bifurcation point being at β = β∗
implying R0 = 1 and there appears a positive locally asymptotically stable infected equilibrium point. There
is an exchange of stability between disease free equilibrium and infected equilibrium at R0 = 1. Hence, a
trans-critical bifurcation takes place at the break point β = β∗. We can summarize this discussion in the
following theorem :
Theorem 3
As R0 of the system crosses unity from below, the disease free equilibrium changes its nature
from being globally asymptotically stable to unstable and there appears an infected equilibrium
which is locally asymptotically stable. Hence a trans-critical bifurcation takes place at R0 = 1.
PARAMETER ESTIMATION
We now numerically depict and verify the results obtained in Local and Global dynamics and Bifurca-
tion Analysis sections. The theoretical results obtained are validated for a set of model parameters using
MATLAB software. The values of ω, µ and µ1, α are approximated and chosen to be from [24] and [12]
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respectively. The rest of the parameter values of the model are estimated minimizing the root mean square
difference between the model predictive output and the experimental data from [13, 28]. All the parameter
values chosen for the model 1 are summarized in the following table.
Table 1. Values of the Model 1 parameters
S.No. Parameters Value
1 ω 10
2 β 0.005
3 µ .05
4 µ1 1.1
5 α 8.2
6 d1 0.027
7 d2 0.22
8 d3 0.1
9 d4 0.428
10 d5 0.01
12 b1 0.1
13 b2 0.1
14 b6 0.08
15 b4 0.11
16 b5 0.1
17 b6 0.07
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NUMERICAL SIMULATIONS
DISEASE FREE EQUILIBRIUM E0
The following table shows different values of parameters chosen so as to obtain the phase portraits of the
system for the case R0 < 1.
Table 2. Values of the Model parameters : R0 < 1
S.No. Parameters Value
1 ω 2
2 β 0.05
3 µ .1
4 µ1 .1
5 α 0.5
6 d1 0.027
7 d2 0.22
8 d3 0.1
9 d4 0.428
10 d5 0.01
11 d6 0.01
12 b1 0.1
13 b2 0.1
14 b6 0.08
15 b4 0.11
16 b5 0.1
17 b6 0.07
For the above set of parameter values, R0 = 0.77 < 1. Since R0 < 1, we can say that the disease free
equilibrium point, E0 = (20, 0, 0) is globally asymptotically stable. The following figures(1-2) shows the
global stability of the infection free equilibrium E0 .
Figure 2 shows the global asymptotic stability of E0 = (20, 0, 0). It is obtained using different initial
conditions for the same set of the model parameters given in Table 2
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Figure 1. Initial condition: (S0, E0, I0) = (30, 5, 10)
Figure 2. 3-d plot of the system for R0 < 1.
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INFECTED/ENDEMIC EQUILIBRIUM E1
We know that the infected equilibrium E1 exists only if R0 > 1 and it is also locally asymptotically stable
when R0 > 1. For the parameter values in the following table 3 the value of R0 was calculated to be 1.929
and E1 = (25.9, 2.44, 1.85). Figure 3 demonstrates that E1 is locally asymptotically stable whenever R0 > 1.
Table 3. Values of the Model parameters : R0 > 1
S.No. Parameters Value
1 ω 5
2 β 0.05
3 µ .1
4 µ1 .1
5 α 0.5
6 d1 0.027
7 d2 0.22
8 d3 0.1
9 d4 0.428
10 d5 0.01
11 d6 0.01
12 b1 0.1
13 b2 0.1
14 b6 0.08
15 b4 0.11
16 b5 0.1
17 b6 0.07
Figure 3. Initial condition: (S0, E0, I0) = (30, 15, 5)
TRANSCRITICAL BIFURCATION
In this section, we numerically show that as R0 crosses unity from below, there is an exchange of stability
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between the disease free equilibrium and infected equilibrium. Here the parameter ω is varied in the interval
(0, 5) in steps of 0.1. The other parameters chosen are given in the following table 5. As a result R0 varies
in the interval (0, 3). Figure 4 depicts the trans-critical bifurcation at R0 = 1.
Table 4. Values of the parameters
S.No. Parameters Value
1 β 0.05
2 µ .1
3 µ1 .1
4 α 0.5
5 d1 0.027
6 d2 0.22
7 d3 0.1
8 d4 0.428
9 d5 0.01
10 d6 0.01
11 b1 0.1
12 b2 0.1
13 b6 0.08
14 b4 0.11
15 b5 0.1
16 b6 0.07
Figure 4. Trans-critical Bifurcation
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CHARACTERISTICS OF COVID-19 AND VALIDATION OF THE PROPOSED MODEL
The characteristic features of the disease Covid-19 are as follows:
(a) Target cells(monocytes) deplete to approximately 66 % to the original level (from 6x108 to 4x108 in
severe cases) [28].
(b) Peak viremia approximately occurs during the second week of disease onset [12].
In this section we vary the parameters x = (d1 + d2 + d3 + d4 + d5 + d6) and y = (b1 + b2 + b3 + b4 + b5 + b6)
and do a two parameter heat plot to validate our model 1. The parameters x and y were varied in the
interval (0, 5) and model 1 was able to reproduce both the above characteristic of the Covid-19. Other fixed
parameter values were taken from the following table 5.
Table 5. Parameter values
S.No. Parameters Value
1 ω 10
2 β 0.005
3 µ .05
4 µ1 1.1
5 α 8.2
We choose the parameters x and y in the x− axis and y− axis respectively and vary them to check for
reproduction of the characteristics (a) and (b).
In figure 5 model 1 is able to recover the first characteristic (a) exactly for the parameter values in the region
pointed by the arrow. In this region with yellow colour the final fraction of uninfected cells after infection
lies between (60− 70)% and for the parameter values in this region the model 1 is able to reproduce the first
characteristic (a).
The region with yellow colour in figure 6 pointed by the arrow is the region where model 1 is able to recover
the second characteristics (b). Time to peak viremia lies between 8-16 days in the region. Hence for the
parameter values in this region our model is able to reproduce the second characteristics (b).
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Figure 5. Initial condition: (S0, E0, I0)= (6x108, 0, 1)
Figure 6. Initial condition: (S0, E0, I0) = (6x108, 0, 1)
SENSITIVITY ANALYSIS
From the previous sections, it is clear that the infected cell population and the virus load die out when
R0 < 1. Therefore it is important to control the model parameters in a manner which will make R0 less than
one. Thus, determining the intervals in which the model parameters are sensitive becomes vital. As each
parameter is varied in different intervals, the infected cell population, mean infected cell population and the
mean square error are plotted with respect to time. These plots are used to determine the sensitivity of the
parameter. The different intervals chosen are given in the following Table 6. For all the plots in this section,
the time scale is the following: x−axis: 10 units = 1 day, y− axis: 1 unit = 1 cell.
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Table 6. Sensitivity Analysis
Parameter Interval Step Size Other Parameters
u11 0 to 0.4 0.01 ω = 10, β = 0.005, µ = 0.05
0.4 to 0.8 µ1 = 1.1, u12 = 0.6240, α = 0.7
0.8 to 0.1 0.001
u12 0 to 1 0.05 ω = 10, β = 0.005, µ = 0.05
1 to 2 µ1 = 1.1, u11 = 1.0238, α = 0.7
β 0 to 0.01 0.001 ω = 10, u11 = 1.0238, µ = 0.05
0.01 to 0.02 µ1 = 1.1, u12 = 0.6240, α = 0.7
0.02 to 0.03
α 0.5 to 1.2 0.01 ω = 10, β = 0.005, µ = 0.05
1.2 to 3 µ1 = 1.1, u12 = 0.6240, u11 = 1.0238
3 to 4 0.05
ω 5 to 15 0.1 β = 0.005, u11 = 1.0238, µ = 0.05
20 to 40 µ1 = 1.1, u12 = 0.6240, α = 0.7
40 to 60
µ 0.001 to 0.015 0.0001 ω = 10, β = 0.005, u11 = 1.0238
0.01to 0.03 µ1 = 1.1, u12 = 0.6240, α = 0.7
0.03 to 0.08
µ1 0.01 to 0.1 0.001 ω = 10, β = 0.005, µ = 0.05
0.1 to 0.4 0.01 u11 = 1.0238, u12 = 0.6240, α = 0.7
0.4 to 1.8
3.0.1 Parameter α
1. Interval I : 0.5 to 1.2 : The results related to sensitivity of α, varied from 0.5 to 1.2 in step size of
0.01 are shown in the Figure (7). The parameter α is not sensitive to the system in this interval.
Figure 7. Sensitivity Analysis of α in Interval I.
2. Interval II : 1.2 to 3 : The results related to sensitivity of α, varied from 1.2 to 3 in step size of
0.01, are shown in the Figure (8). The parameter α is sensitive to the system in this interval.
3. Interval III : 3 to 4 : The results related to sensitivity of α, varied from 3 to 4 in step size of 0.05,
are shown in the Figure (9). The parameter α is not sensitive to the system in this interval.
We conclude from these plots that the parameter α is sensitive in interval II and insensitive in I and
III. To confirm and validate the same, we have plotted the infected population for each varied value of
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Figure 8. Sensitivity Analysis of α in Interval II.
the parameter α per interval in Figure (10).
Figure 9. Sensitivity Analysis of α in Interval III.
(a) Interval I
3.0.2 Parameter µ1
1. Interval I : 0.01 to 0.1 : The results related to sensitivity of µ1, varied from 0.01 to 0.1 in step
size of 0.001 are shown in the Figure (11). The parameter µ1 is sensitive to the model system in this
interval.
2. Interval II : 0.1 to 0.4 : The results related to sensitivity of µ1, varied from 0.1 to 0.4 in step size of
0.01 are shown in the Figure (12). The parameter µ1 is sensitive to the model system in this interval.
3. Interval III : 0.4 to 1.8 : The results related to sensitivity of µ1, varied from 0.4 to 1.8 in step size
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(b) Interval II (c) Interval III
Figure 10. Sensitivity Analysis of α. Infected cell population in different intervals.
of 0.01 are shown in the Figure (13). The parameter µ1 is not sensitive to the model system in this
interval.
We conclude from these plots that the parameter µ1 is sensitive in interval I and II and insensitive in interval
III. To confirm and validate the same, we have plotted the infected population for each varied value of the
parameter µ1 per interval in Figure (14). In similar lines, sensitivity analysis is done for other parameters
and the results are summarized in Table (7). The corresponding plots are given in Appendix - A owing to
the brevity of the manuscript.
Figure 11. Sensitivity Analysis of µ1 in Interval I.
Figure 12. Sensitivity Analysis of µ1 in Interval II.
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Figure 13. Sensitivity Analysis of µ1 in Interval III.
(a) Interval I
Table 7. Summary of Sensitivity Analysis
Parameter Interval Sensitivity
u11 0 to 0.4 ×
0.4 to 0.8 ×
0.8 to 1 ×
u12 0 to 1 ×
1 to 2 ×
β 0 to 0.01 ×
0.01 to 0.02 ×
0.02 to 0.03 ×
α 0.5 to 1.2 ×
1.2 to 3 X
3 to 4 ×
ω 5 to 15 ×
20 to 40 ×
40 to 60 ×
µ 0.001 to 0.015 ×
0.01 to 0.03 ×
0.03 to 0.08 ×
µ1 0.01 to 0.1 X
0.1 to 0.4 X
0.4 to 1.8 ×
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(b) Interval II (c) Interval III
Figure 14. Sensitivity Analysis of µ1. Infected cell population in different intervals.
4 DRUG INTERVENTIONS AND OPTIMAL CONTROL STUDIES
OPTIMAL CONTROL PROBLEM
In this section, we will formulate an optimal control problem for the model 2 with drug interventions as
control. The controls to be considered are:
1. Drug intervention to boost immune response: The innate immune response that is inherent in
the human body is the first to counter and reduce the growth of infected cells and viral load. In this
intervention, we provide medication that boosts this innate immune system. This is modelled using
two controls based on their role:
(a) Control intervention that reduces the growth of the infected cells by releasing the necessary
cytokines and chemokines which act on these cells. We denote this intervention by control variable
u11(t).
(b) Control intervention that reduces the the viral load by releasing the necessary cytokines and
chemokines. We denote this intervention by control variable u12(t).
2. Drug intervention to prevent viral replication: We know that one of the main causes of severity
of disease caused by viruses is their rapid replication in the human body. We consider the intervention
of providing medication that directly acts on the virus cells and prevent its replication which in turn
reduces the birth rate of the virus. We use the control variable u2(t) to denote this intervention.
The set of all admissible controls is given by
U = {(u11(t), u12(t), u2(t)) : u11(t) ∈ [0, u11max], u12(t) ∈ [0, u12max], u2(t) ∈ [0, u2max], t ∈ [0, T ]}
Without medical interventions, u11, u12, and u2 are just constant parameters with u2 = 0. u11 and u12
have some value based on the inherent release of these cytokines and chemokines by the body. In the control
problem, these variables are considered as functions of time. The upper bounds of control variables are based
on the resource limitation based on availability and the limit to which these drugs would be prescribed to
the patients.
Since these antiviral drugs administered are not inherently present in the human body and being foreign
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particles to the body, there could be side effects once administered. Also cost of these drugs could be an
issue that needs to be addressed.
Based on these we now propose and define the optimal control problem with the goal to reduce the cost
functional
J(u11(t), u12(t), u2(t)) =
∫ T
0
(I(t) + V (t) +A1u11(t)
2 +A2u12(t)
2 +A3u2(t)
2)dt Equation 4.1.
such that u = (u11(t), u12(t), u2(t)) ∈ U
subject to the system
dS
dt
= ω − βSV − µS
dI
dt
= βSV − µI − (u11(t))I
dV
dt
= (α− u2(t))I − µ1V − (u12(t))V Equation 4.2.
The integrand of the cost function (4.1), denoted by
L(S, I, V, u11, u12, u2) = (I(t) + V (t) +A1u11(t)
2 +A2u12(t)
2 +A3u2(t)
2)
is called the Lagrangian or the running cost.
Here, the cost function represents the number of infected cells and viral load throughout the observation
period, and the side effects of the drug on the body. Effectively, we want to minimize the infected cells and
the virus load in the body with the optimal medication that is also least harmful to the body. Since the
drugs administered have multiple effects, the non-linearity for the control variables in the objective become
justified [15].
The admissible solution set for the Optimal Control Problem (4.1)-(4.2) is given by
Ω = {(S, I, V, u11, u12, u2) | S, I and V that satisfy (4.2), ∀ u ∈ U}
EXISTENCE OF OPTIMAL CONTROL
We will show the existence of optimal control functions that minimize the cost functions within a finite time
span [0, T ] showing that we satisfy the conditions stated in Theorem 4.1 of [14].
Theorem 4.1. There exists a 3-tuple of optimal controls (u∗11(t), u∗12(t), u∗2(t)) in the set of admissible
controls U such that the cost functional is minimized i.e.,
J [u∗11(t), u
∗
12(t), u
∗
2(t)] = min
(u∗11,u
∗
12,u
∗
2)∈U
{
J [u11, u12, u2]
}
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corresponding to the optimal control problem (4.1)-(4.2).
Proof. In order to show the existence of optimal control functions, we will show that the following conditions
are satisfied :
1. The solution set for the system (4.2) along with bounded controls must be non-empty, i.e., Ω 6= φ.
2. U is closed and convex and system should be expressed linearly in terms of the control variables with
coefficients that are functions of time and state variables.
3. The Lagrangian L should be convex on U and L(S, I, V, u11, u12, u2) ≥ g(u11, u12, u2), where g(u11, u12, u2)
is a continuous function of control variables such that |(u11, u12, u2)|−1g(u11, u12, u2) → ∞ whenever
|(u11, u12, u2)| → ∞, where |.| is an l2(0, T ) norm.
Now we will show that each of the conditions are satisfied :
1. From Positivity and boundedness of solutions of the system(4.2), all solutions are bounded for each
bounded control variable in U.
Also,the right hand side of the system (4.2) satisfies Lipschitz condition with respect to state variables.
Hence, using the positivity and boundedness condition and the existence of solution from Picard-Lindelof
Theorem[23], we have satisfied condition 1.
2. U is closed and convex by definition. Also, the system (4.2) is clearly linear with respect to controls such
that coefficients are only state variables or functions dependent on time. Hence condition 2 is satisfied.
3. Choosing g(u11, u12, u2) = c(u211 + u212 + u22) such that c = min {A1, A2, A3}, we can satisfy the condition
3.
Hence there exists a control 3-tuple (u∗11, u∗12, u∗2) ∈ U that minimizes the cost function (4.1).
CHARACTERIZATION OF OPTIMAL CONTROL
We will obtain the necessary conditions for optimal control functions using the Pontryagin’s Maximum
Principle [19] and also obtain the characteristics of the optimal controls.
The Hamiltonian for this problem is given by
H(S, I, V, u11, u12, u2, λ) := L(S, I, V, u11, u12, u2) + λ1
dS
dt
+ λ2
dI
dt
+ λ3
dV
dt
Here λ = (λ1,λ2,λ3) is called co-state vector or adjoint vector.
Now the Canonical equations that relate the state variables to the co-state variables are given by
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dλ1
dt
= −∂H
∂S
dλ2
dt
= −∂H
∂I
dλ3
dt
= −∂H
∂V
Equation 4.3.
Substituting the Hamiltonian value gives the canonical system
dλ1
dt
= λ1(βV + µ)− λ2βV
dλ2
dt
= −A1 + λ2(µ+ u11)− λ3(α− u2)
dλ3
dt
= −A2 + λ1βS − λ2βS + λ3(µ1 + b7 + u12)
Equation 4.4.
along with transversality conditions λ1(T ) = 0, λ2(T ) = 0, λ3(T ) = 0.
Now, to obtain the optimal controls, we will use the Hamiltonian minimization condition ∂H∂ui = 0 , at ui = u
∗
i
for i = 11, 12 , 2.
Differentiating the Hamiltonian and solving the equations, we obtain the optimal controls as
u∗11 = min
{
max
{
λ2I
2A1
, 0
}
, u11max
}
u∗12 = min
{
max
{
λ3V
2A2
, 0
}
, u12max
}
u∗2 = min
{
max
{
λ3I
2A3
, 0
}
, u2max
}
NUMERICAL SIMULATIONS
In this section, we perform numerical simulations to understand the efficacy of multiple drug interventions.
This is done by studying the effect of control on the dynamics of the system. These simulations also validate
the theoretical results obtained in the previous section.
The various combinations of controls considered are:
1. Providing medication that only boosts the innate immune system by reducing the number of infected
cells and viral load.
2. Providing medication and treatment that only prevents viral replication.
3. Providing medication and treatment that execute both the above.
For our simulations, we have taken the total number of days as T = 30. The parameter values considered
are as follows : ω = 10, µ= 0.05, µ1 = 1.1, β = 0.005, α = 0.5
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We first solve the state system numerically using Fourth Order Runge-Kutta method in MATLAB without
any interventions. We take the initial values of state variables to be S(0) = 3.2 × 105, I(0) = 0, V (0) = 5.2
[5, 12] with the control parameters as constant values u11 = 0.8866, u12 = 0.56, u2 = 0.
Now, to simulate the system with controls, we use the Forward-Backward Sweep method stating with the
initial values of controls and solve the state system forward in time. Following this we solve the adjoint state
system backward in time due to the transversality conditions, using the optimal state variables and initial
values of optimal control.
Now, using the values of adjoint state variables, the values of optimal control are updated and with these
updated control variables, we go through this process again. We continue this till the convergence criterion
is met [19]. The positive weights chosen for objective coefficients are A1 = 80, A2 = 80, A3 = 7480. A3
is chosen high compared to A1 and A2 as the effort to stop the viral replication process is higher than the
effort to enhance innate immune response as it is already existing in human body.
Figure 15. S, I, V without controls
Figure 15 shows the change in the cell population S(t), I(t), V (t) respectively with time. We observed that
the susceptible cells reduce and the infected cells increase exponentially due to the increase in viral load over
a period of time.
Figure 16 shows the behaviour of susceptible cells under all possible combinations of control. We observe that
in the presence of immune boosting medication only, there is a slight reduction in the number of susceptible
cells getting infected by the virus but when viral replication is prevented the impact is more. Even lesser
damage is seen on susceptible cells when all control interventions are applied together.
In figure 17 the first frame shows how infected cells grow or decay with various combinations of controls. The
increase in infected cells is slightly lesser in the presence of immunity boosters. There is a huge difference
if viral replication preventing medicines are used. Here too, the best results are obtained only when all the
controls are applied. The second frame in figure 17 gives detailed view of the cases when only antiviral
replication medicines are used and all 3 controls are used. We see that when only control u2 is used, the
infected cells increase slowly, and reduce later but increase again after 20 days. This may be harmful to the
patient. When all 3 controls are used, the infected cells reach peak around the 8th day and start decaying
then on and even become nearly zero after 30 days.
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Figure 16. S under optimal controls u∗1, u
∗
2
Figure 17. I under optimal controls u∗1, u
∗
2
Figure 18. V under optimal controls u∗1, u
∗
2
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In figure 18 the first frame shows the viral load under all combinations of control interventions. When
no medication is provided, there is exponential increase in the viral load but when only immunity boosting
medication is provided (u2 = 0), there is a little reduction seen in the increase of viral load. The combinations
of both these drug interventions show much better results. From the second frame in figure 18 it can be seen
that when only anti-viral replication medication is provided (u11 = u12 = 0), the viral load becomes very less
by the 5th day but due to the absence of immunity boosters, the viral load tends to increase around 25th
day. The best results are shown when all the control interventions are administered together. The detailed
view of the figure explains how the viral population tends to become nearly zero around 7th day and remains
there throughout. These results are in line with the clinical findings discussed in [6].
Thus the optimal control studies and the numerical simulations help us to infer the following :
1. Innate immunity boosters do affect the way infection spreads in the body but they become effective only
along with the prevention of viral replication medicines.
2. Viral replication, when prevented, reduces the infected cells and the viral load drastically but the immune
system needs to be sufficiently boosted if we want to completely cure the patient.
3. When all controls are used effectively, then the patient can be cured completely, with minimal/optimal
dosage of drugs which minimizes the side effects caused to the patient when administered.
5 DISCUSSIONS AND CONCLUSIONS
The outbreak of novel coronavirus in Wuhan, China marked the introduction of a virulent coronavirus
into human society. On Feb. 11, 2020, the World Health Organization named novel corona viral pneumonia
induced disease as Coronavirus disease (COVID-19), which is caused by Severe Acute Respiratory Syndrome
coronavirus-2 (SARS-CoV-2). Soon this grew into a global pandemic. As on 02 May 2020, 2, 37, 996 people
lost their lives and more than 33 lakh people have been affected due to COVID-19 all over the world [4].
Although a lot of research is being done, effective approaches to treatment and epidemiological control are
still lacking.
In this context, the invivo mathematical modelling studies can be extremely helpful in understanding the
efficacy of the drug interventions. These studies also can be helpful in understanding the role of the crucial
inflammatory mediators and the behaviour of immune response towards this novel corona virus. Motivated
by these facts, in this paper, we study the invivo dynamics of Covid-19.
Based on the pathogenesis of Covid-19, we have proposed two models. The first model deals with natural
history and the course of infection while the second model incorporates the drug interventions. The results of
these studies show that the disease system admits two steady states: one being the disease free equilibrium
and the other being the infected equilibrium. The dynamics of the system show that the disease takes it
course to one of these states based on the reproduction number R0. Specifically when R0 < 1 the system
tends to stabilize around the disease free equilibrium and when R0 > 1 the system tends to stabilize around
the infected equilibrium. The system also undergoes a trans-critical bifurcation at R0 = 1. This result is
inline with the conclusions made at the population level for Covid-19 [16]. From the sensitivity analysis it
is seen that the burst rate of virus particles and the natural death rate of the virus are sensitive parameters
of the system. From the sensitivity analysis it is seen that the burst rate of virus particles and the natural
death rate of the virus are the sensitive parameters of the system. We also validate the proposed model 1
using two-parameter heat plots that reproduce the characteristics of Covid-19.
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Results from the optimal control studies suggest that the antiviral drugs that target on viral replication and
the drugs that enhance the immune system response both reduce the infected cells and viral load when taken
individually. In particular, the antiviral drugs that target viral replication seem to yield better results than
the drugs that enhance the innate immune response. From figure 18, it can be seen that on administering
control intervention u2 there is a substantial decrease in the viral load from day 2. This result validates the
clinical findings in [6] which states that "Ivermectin, an FDA-approved anti-parasitic previously shown to
have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a
single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect 5000-fold reduction
in viral RNA at 48 h."
When applied in combination, these drugs yield the best possible results. Hence, the optimal control
strategy and the best drug regime would be to use the combination of both these drugs which help in
patient’s recovery with minimal/optimal dosage that reduce the side effects caused due to these drugs.
This invivo modelling study involving the crucial biomarkers of Covid-19 is first of its kind for Covid-
19 and the results obtained from this can be helpful to researchers, epidemiologists, clinicians and doctors
working in this field.
6 FUTURE RESEARCH
This work is an initial attempt to understand the basic dynamics of Covid-19 and its course. The conse-
quences and the outcomes of the two main functions of antiviral drug interventions is modelled and discussed.
Further research can be focused on incorporating the side effects of these drugs into the model. Future studies
can also focus on the various other drug interventions along with their effects on Covid-19 dynamics.
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7 APPENDIX - A
SENSITIVITY PLOTS FOR OTHER PARAMETERS
For all the plots in this section, the time scale is the following: x−axis: 10 units = 1 day, y− axis: 1 unit =
1 cell.
7.1 Parameter u12
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Figure 19. Sensitivity Analysis of u12 in Interval I.
Figure 20. Sensitivity Analysis of u12 in Interval II.
(a) Interval I (b) Interval II
Figure 21. Sensitivity Analysis of u12. Infected cell population in different intervals.
7.2 Parameter u11
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Figure 22. Sensitivity Analysis of u11 in Interval I.
Figure 23. Sensitivity Analysis of u11 in Interval II.
Figure 24. Sensitivity Analysis of u11 in Interval III.
(a) Interval I
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(b) Interval II (c) Interval III
Figure 25. Sensitivity Analysis of u11. Infected cell population in different intervals.
7.3 Parameter β
Figure 26. Sensitivity Analysis of β in Interval I.
Figure 27. Sensitivity Analysis of β in Interval II.
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Figure 28. Sensitivity Analysis of β in Interval III.
(a) Interval I
(b) Interval II (c) Interval III
Figure 29. Sensitivity Analysis of β. Infected cell population in different intervals.
7.4 Parameter ω
Figure 30. Sensitivity Analysis of ω in Interval I.
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Figure 31. Sensitivity Analysis of ω in Interval II.
Figure 32. Sensitivity Analysis of ω in Interval III.
(a) Interval I
(b) Interval II (c) Interval III
Figure 33. Sensitivity Analysis of ω. Infected cell population in different intervals.
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7.5 Parameter µ
Figure 34. Sensitivity Analysis of µ in Interval I.
Figure 35. Sensitivity Analysis of µ in Interval II.
Figure 36. Sensitivity Analysis of µ in Interval III.
(a) Interval I
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(b) Interval II (c) Interval III
Figure 37. Sensitivity Analysis of µ. Infected cell population in different intervals.
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